Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2015; 5(1): 094-098


Development and Validation of RP-HPLC Method for the Simultaneous Determination of Trimethoprim, Sulfadimidine Sodium and Tylosin Tartrate in injectable solution formulation

Mashhour Ghanem, Saleh Abu-Lafi.




Abstract

A simple, robust and reliable reversed phase HPLC method was developed and validated for the simultaneous determination of Trimethoprim (TMP), Sulfadimidine sodium (SDMS) and Tylosin tartrate (TYT) in Nuroprim® injectable solution formulation. The desired separation was achieved on XBridge C18 column (150 x 4.6 mm i.d., 5µm) at room temperature. The optimized mobile phase consisted of a binary solvent mixture of acetonitrile and aqueous triethylamine (TEA) solution adjusted to pH 5.7 by acetic acid. The mobile phase flow rate was fixed at 1.0 ml/min and the analytes were monitored at 287 nm using photo diode array detector. The effects of the chromatographic conditions on peaks capacity factor, USP tailing factor, column efficiency and resolution were systematically optimized. The method was validated as per International Conference of Harmonization (ICH) and United States Pharmacopeia (USP) guidelines and found to be adequate for the routine quantitative determination of TMP, SDMS and TYT in commercially available Nuroprim® injectable solution dosage form.

Key words: Tylosin Tartrate, Sulfadimidine sodium, Trimethoprim, HPLC, Injectable solution






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.